0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Bilateral Choroidopathy and Serous Retinal Detachments During Ipilimumab Treatment for Cutaneous Melanoma

Dimosthenis Mantopoulos, MD1; Kari L. Kendra, MD, PhD2; Alan D. Letson, MD1; Colleen M. Cebulla, MD, PhD1
[+] Author Affiliations
1Havener Eye Institute, Department of Ophthalmology and Visual Science, The Ohio State University, Wexner Medical Center, Columbus
2Department of Internal Medicine, Division of Medical Oncology, The Ohio State University, Wexner Medical Center, Columbus
JAMA Ophthalmol. 2015;133(8):965-967. doi:10.1001/jamaophthalmol.2015.1128.
Text Size: A A A
Published online

Extract

Several immune-related toxic effects have been reported with ipilimumab therapy for cutaneous melanoma. We describe a novel reaction, to our knowledge, involving the choroidal vasculature and resulting in bilateral serous retinal detachments without overt inflammatory signs.

Article InformationCorresponding Author: Colleen M. Cebulla, MD, PhD, Havener Eye Institute, Department of Ophthalmology and Visual Science, The Ohio State University, 915 Olentangy River Rd, Ste 5000, Columbus, OH 43212 (colleen.cebulla@osumc.edu).

Published Online: May 14, 2015. doi:10.1001/jamaophthalmol.2015.1128.

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

Funding/Support: This work was supported by grant K08EY022672 from the National Eye Institute and by the Ohio Lions Eye Research Foundation and the Patti Blow Fund. ECOG 1609 provided drug and support for the clinical trial.

Role of the Funder/Sponsor: The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure.
Serous Detachments and Choroidopathy After Ipilimumab Therapy

A-E, Color fundus photograph (A), autofluorescence photograph (B), spectral-domain optical coherence tomographic image (N indicates nasal; S, superior, and T, temporal) (C), fluorescein angiographic image (D), and indocyanine green angiographic image (E) before dexamethasone treatment. D, The fluorescein lacks abnormal hyperfluorescence. E, Arrowheads indicate staining of small and midsized choroidal vessels; box, area shown in G. F, Spectral-domain optical coherence tomographic image following dexamethasone treatment (T indicates temporal; pink line, foveal center). G, Magnified inset from E showing indocyanine green staining of small and midsized choroidal vessels (arrowheads).

Graphic Jump Location

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

351 Views
2 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();